Send us Feedback

Axcan Pharma (AXCA)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW
Fmr Diamondback Manager, Anthony Scolaro, Gets Probation for Insider Trade
Forbes  Aug 2  Comment 
Anthony Scolaro was approached by two FBI agents on November 2, 2009 who told him that they had information that he had traded on inside information related to the healthcare company Axcan (Nasdaq:AXCA).  He got a lawyer, William Brodsky, who...
Biotech spin-out grabs $76M in venture cash for antibiotic work
FierceBiotech  Nov 9  Comment 
Just a few months after Axcan swept in to buy up the San Diego-based Mpex and its lead antibiotic program, the former CEO of the developer has successfully spun out the rest of the pipeline into a new company dubbed Rempex and snagged venture...
[$] Manager Is Cooperating in Inquiry
Wall Street Journal  May 18  Comment 
Former Diamondback portfolio manager Anthony Scolaro pleaded guilty in connection with insider trading last year and is cooperating with prosecutors.
Diamondback Capital’s Scolaro Pleaded Guilty in 2010, Unsealed Papers Show
Bloomberg  May 18  Comment 
Hedge Funds: Ex-Diamondback manager’s plea unsealed
MarketWatch  May 18  Comment 
Ex-Diamondback manager's guilty plea unsealed
MarketWatch  May 18  Comment 
Defendant Related to Galleon Case Pleads Guilty
Wall Street Journal  Apr 26  Comment 
A trader whose phone conversations were the first known to be monitored secretly by federal agents in the insider-trading investigation related to the Galleon Group hedge fund pleaded guilty in the case.
Societe generale de financement du Quebec to help fund Axcan acquisition
Canadian Business  Feb 14  Comment 
MONTREAL - Societe generale de financement du Quebec, a holding company for the provincial government, says it will provide a US$14.7 million
[$] Axcan to Buy Specialty Drug Firm Eurand
Wall Street Journal  Dec 1  Comment 
Eurand agreed to be acquired by Axcan Holdings for $583 million, after an "extended auction process" for the Netherlands specialty pharmaceutical company.
Axcan to buy Eurand for $583 million
FierceBiotech  Dec 1  Comment 
Axcan Holdings has struck a deal to buy Eurand for $583 million. Shareholders are in line for $12 a share, a meager 9.4 percent premium over yesterday's close. "The last several years have seen Eurand evolve" from a licensing and drug developer...




more ▼WIKI ANALYSIS
This company is or has gone private. Information about the company may be limited and outdated.
 




References

Retrieved from "http://www.wikinvest.com/stock/Axcan_Pharma_(AXCA)"
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki